The intrathecal catheter creates a pathway for medication flowing from the pump to the drug delivery site. Medtronic intrathecal catheters come in one - and two - piece models. The silicone, radiopaque catheter body is elastic, flexible, and trimmable.
| Model 8709SC | Model 8731SC | |
| Total length | 89 cm | 104.1 cm |
| Spinal segment | 81.4 cm | 38.1 cm |
| Pump segment or SC interface | 7.6 cm | 66 cm |
| Connector pin | Yes | Yes |
| Pin type | Sutureless | Suture grooves |
| Introducer needle | 15-gauge Tuohy | 15-gauge Tuohy |
| Needle length | 9.3 cm | 11.4 cm/9.3 cm |
| Numeric markings | Yes | Yes |
| Trimmable segments | Spinal | Spinal/pump end |
The Indura® 1P 8709SC intrathecal catheter consists of a one-piece catheter body and a catheter interface with the sutureless pump connector designed for use in the intrathecal space. Made of radiopaque silicone rubber, it is flexible and trimmable at the pump end of the placed catheter. The sutureless pump connector allows for connection to the pump at the catheter port.
The spinal end of the catheter has a closed tip and 6 holes for fluid delivery. To aid in catheter placement, it is marked at 1-cm increments between 12 cm and 81 cm. A guide wire in the lumen provides additional stiffness and catheter tip control during placement. The catheter can be positioned by direct percutaneous surgical procedures using the accessories provided in the catheter package.

| LENGTH | ||
| Total catheter | 89 cm | |
| Spinal segment | 81.4 cm | |
| Catheter interface with sutureless connector | 7.6 cm | |
| CATHETER | ||
| Outer diameter | 1.4 mm (4.2 French) | |
| Inner diameter | 0.53 mm | |
| Marker spacing | 1 cm between 12 cm and 81 cm | |
| CATHETER INTERFACE | ||
| Outer diameter (catheter only) | 2.2 mm (6.5 French) | |
| Inner diameter (catheter only) | 0.53 mm | |
| OTHER SPECIFICATIONS | ||
| Catheter volume | 0.0022 mL/cm | |
| Connector pin inner diameter | 0.41 mm | |
| Guide wire outer diameter | 0.46 mm | |
| Introducer needle | 15-gauge Tuohy 9.3 cm | |
| Trimmable end | Pump end of the catheter | |
| CATHETER MATERIALS | ||
| Body | Radiopaque silicone rubber | |
| Tip | Closed tip, radiopaque, titanium with 6 side holes | |
| Catheter Interface | Radiopaque silicone rubber (7.6 cm) | |
| Sutureless Pump Connector | Radiopaque silicone, titanium, silicone (external component), nylon | |
This reference manual contains information specifically regarding indications, drug stability and emergency procedures for the SynchroMed and IsoMed Infusion Systems.
This technical manual includes the instructions for use for the Indura® 1P model 8709SC.
This guide describes a low-complication catheter implant procedure for the 8709SC and 8731SC catheters.
Information for prescribers for the SynchroMed II model 8637 Programmable Pump.
The Model 8731SC Intrathecal Catheter is a 2-piece catheter. The catheter body is made of an elastic and flexible radiopaque silicone rubber material, and includes trimmable segments.
The sutureless connector facilitates connection to the pump at the catheter port. The pre-attached strain-relief sleeve and connector pin facilitate connection to the spinal catheter segment.
The distal end of the spinal segment has a closed tip and 6 side holes for fluid delivery. The spinal segment is marked in 1-cm increments starting at the 14-cm mark to aid in catheter placement. A guide wire in the lumen provides additional stiffness and catheter tip control during placement. The catheter can be positioned by direct percutaneous surgical procedures using the accessories provided in the catheter package.

| LENGTH | ||
| Total catheter | 104.1 cm | |
| Spinal segmenta | 38.1 cm | |
| Pump segmentb | 7.6 cm | |
| SPINAL SEGMENT | ||
| Outer diametera | 1.4 mm (4.2 French) | |
| Inner diametera | 0.53 mm | |
| Marker spacinga | 1 cm starting at 14 cm | |
| Catheter tipa | Closed with 6 side holes | |
| PUMP SEGMENTS | ||
| Outer diameterb | 2.2 mm (6.5 French) | |
| Inner diameterb | 0.53 mm | |
| OTHER SPECIFICATIONS | ||
| Catheter volumea,b | 0.0022 mL/cm | |
| Connector pin | 0.41 mm inner diameter | |
| Guide wire outer diameter | 0.46 mm | |
| Introducer needle (long)a | 15-gauge Tuohy (11.4 cm) | |
| Introducer needle (short)a | 15-gauge Tuohy (9.3 cm) | |
| Trimmable segments | spinal and pump segments | |
| CATHETER MATERIALSb | ||
| Body | Radiopaque silicone rubber | |
| Tip | Closed tip, radiopaque, titanium with 6 side holes | |
| Catheter Interface | Radiopaque silicone rubber (7.6 cm) | |
| Sutureless Pump Connector | Radiopaque silicone, titanium, silicone (external component), nylon | |
a Included in or applies to the Model 8598A Intrathecal Catheter Spinal Revision Kit
b Included in or applies to the Model 8596SC Pump Segment Revision Kit
This reference manual contains information specifically regarding indications, drug stability and emergency procedures for the SynchroMed and IsoMed Infusion Systems.
This technical manual includes the instructions for use for the Intrathecal Catheter and Sutureless Connector model 8731SC.
This guide describes a low-complication catheter implant procedure for the 8709SC and 8731SC catheters.
Information for prescribers for the SynchroMed II model 8637 Programmable Pump.
For more information on the indications, contraindications, warnings, and precautions for the SynchroMed programmable infusion systems, please review the device brief summaries for the SynchroMed II Drug Infusion System and the SynchroMed EL Infusion System.
ITB TherapySM (Intrathecal Baclofen Therapy) is indicated for use in the management of severe spasticity. For spasticity of spinal cord origin, ITB Therapy via an implantable infusion system should be reserved for patients unresponsive to oral baclofen or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long-term intrathecal baclofen therapy.
Indications, Safety & Warnings for ITB Therapy: Intrathecal Baclofen Withdrawal: Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death.
Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at risk (e.g., spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen).
This therapy is contraindicated in patients who are hypersensitive to baclofen. Implantation of the infusion system is contraindicated if the patient is of insufficient body size, requires a pump implant deeper than 2.5 cm, or, in the presence of spinal anomalies or active infection.
The most frequent drug adverse events vary by indication but include: hypotonia (34.7%), somnolence (20.9%), headache (10.7%), convulsion (10.0%), dizziness (8.0%), urinary retention (8.0%), nausea (7.3%), and paresthesia (6.7%). Pump system component failures leading to pump stall, or dosing/programming errors may result in clinically significant overdose or underdose. Acute massive overdose may result in coma and may be life threatening.
The most frequent and serious adverse events related to device and implant procedures are catheter dislodgement from the intrathecal space, catheter break/cut, and implant site infection including meningitis. Electromagnetic interference (EMI) and Magnetic resonance imaging (MRI) may cause patient injury, system damage, operational changes to the pump, and changes in flow rate.
Please refer to the full prescribing information and system information for details or call Medtronic at 1-800-328-0810. Rx Only. Lioresal® is a registered trademark of Novartis Pharmaceuticals Corporation.
January 2008